Paul Heugh comments as Pfizer confirms record $160bn deal for Allergan, Daily News, 23 November 2015

In this article on the merger between Pfizer and Allergan, Paul Heugh commented “that while “$2bn of savings in the first three years, together with an attractive tax inversion sounds like a compelling reason for a merger, there is no getting away from the fact that less than half of deals fail to attain the objectives stated in the merger announcement”
Read the full article